



Stereotaxic biopsy of the brain under MR imaging control.

D G Thomas, C H Davis, S Ingram, J S Olney, G M Bydder and I R Young

AJNR Am J Neuroradiol 1986, 7 (1) 161-163
<http://www.ajnr.org/content/7/1/161.citation>

This information is current as
of July 1, 2025.

Stereotaxic Biopsy of the Brain under MR Imaging Control

D. G. T. Thomas,¹ C. H. Davis,¹ S. Ingram,² J. S. Olney,³ G. M. Bydder,³ and I. R. Young⁴

Stereotaxic biopsy under computed tomographic (CT) control has become a routine procedure in neurosurgical practice and has a high degree of accuracy with a low morbidity [1–4]. Magnetic resonance (MR) imaging has some advantages over CT in studying the brain and may reveal cerebral lesions where little or no sign is evident with CT [5, 6]. The MR imaging features not seen with CT are usually well localized although in pathologic terms they are often nonspecific. These findings have provided a strong stimulus for the development of stereotaxic biopsy techniques suitable for MR imaging, in part to exploit the new diagnostic information and in part to achieve a better understanding of its significance.

Leksell et al. [7, 8] recently described a stereotaxic system suitable for use with MR imaging as well as the use of conventional MR imaging to confirm the location of bilateral lesions produced in the thalami under CT guidance, but the use of MR imaging-guided stereotaxic biopsy in clinical practice has not been reported previously. We describe a different type of stereotaxic biopsy system suitable for use with MR imaging and illustrate its use in two clinical cases.

Instrumentation

Stereotaxic Frame

A prototype frame developed by Trent Wells (Southgate, CA) and distributed by Radionics (Burlington, MA) and RDG Electro Medical Equipment (Croydon, Surrey, UK) was used in this study. The frame is similar to that used for CT stereotaxic biopsy [9–11] except that no ferromagnetic material is used; closed metal loops that might conduct eddy currents are avoided; and MR-sensitive material is used in the coordinate indicators. The specific modifications were as follows: (1) The standard aluminum alloy/carbon-fiber base ring was replaced with a nonmetallic paxolin/carbon-fiber structure (fig. 1); (2) The ferromagnetic stainless-steel skull fixation pins were replaced with titanium; (3) The metallic components in the base ring attachment were replaced by paxolin and the carbon-fiber rod coordinate indicators were replaced by carbon-fiber tubes containing a solution of Gd-DTPA with a T1 of about 200 msec, enabling them to be seen on MR scans when appropriately windowed (fig. 2). There were also 12

carbon-fiber tubes rather than the nine rods used with the CT system. The latter configuration required a new computer program to calculate the target position.

MR Imaging System

The imaging system used with the stereotaxic frame has been described previously [12]. A two-turn saddle receiver coil (diameter, 29 cm) was placed around the stereotaxic frame, and the patient was placed in the magnet in the usual way. The transmitter coil was unchanged. Inversion-recovery (IR 1500/500/44) and spin-echo (SE 1500/80) pulse sequences were used.

Technique

The base ring was attached to the skull under local anesthesia, and sedation was maintained with intravenous mada-




Fig. 1.—Stereotaxic frame with coordinate indicators surrounding patient's head.

Received March 26, 1985; accepted after revision August 5, 1985.

¹ Department of Neurological Surgery, National Hospitals for Nervous Diseases, Queen Square, London WC1 3BG, United Kingdom. Address reprint requests to D. G. T. Thomas.

² Department of Anaesthetics, National Hospitals for Nervous Diseases, London WC1 3BG, United Kingdom.

³ Department of Radiology, University of London, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 0HS, United Kingdom.

⁴ Picker International, Wembley, Middlesex HA9 7PR, United Kingdom.




Fig. 2.—MR scan showing pattern made by 12 coordinate indicators.

zelam (Hypnovel, Roche). Single-slice contiguous IR 1500/500/44 and SE 1500/80 sections of 8-mm thickness were imaged and the coordinates of the indicators and of the target areas were obtained directly from the MR visual display unit. This information was used to calculate the angles and depths for the target areas. The patient was then transferred to an operating theater separate from the MR suite, fully anesthetized, intubated, and prepared for a burr hole. The arc system was attached and the calculated parameters were used to obtain biopsies from the target areas.

Case Reports

Case 1

A 68-year-old mildly hypertensive woman had been admitted 3 years earlier with ictal onset of a right-sided hemiparesis; this gradually improved, leaving a slight deficit. Two years later she presented with grand mal seizure and transient worsening of her right hemiparesis. A CT scan showed an illdefined region of low attenuation in the left frontal lobe. The lesion appeared unchanged on a CT scan 7 months later but on a follow-up CT scan 11 months later, the lesion had increased in size (fig. 3A). The lesion was seen also on the IR 1500/500/44 scan (fig. 3B) and displayed a central ring. Biopsy of five target areas within the ring, at the margin of the ring, and outside the ring was performed, and histology revealed an oligodendroglioma from the target area within the central ring and reactive gliosis outside the ring.

Case 2

A 38-year-old man had been admitted 2 years earlier with a history of epilepsy associated with left-sided weakness. The CT scan at that time suggested a diffuse right-sided intracerebral tumor, and he underwent a craniotomy and open biopsy. Although no specific

pathologic diagnosis was obtained from the biopsy material, he was treated with radiotherapy. After some improvement over a period of 4 months, he presented again with left-sided weakness, ataxia, and slow mentation. A CT scan at this time displayed calcification in the right thalamus, hypothalamus, and deep temporal region as well as a cavity attributable to his previous surgery. MR imaging was performed before surgery, after the radiotherapy, and before stereotactic biopsy. The latter two scans showed considerable regression of the initial changes, but the features were nonspecific (fig. 4). Biopsy was performed, and histology showed changes compatible with radiation therapy. No tumor tissue was identified. The precise diagnosis remains uncertain.

Discussion

The modifications that are necessary to adapt standard CT stereotactic frames for use in MR imaging are relatively straightforward. Ferromagnetic materials must be avoided, and closed conducting loops must be eliminated to avoid artifact from eddy currents. Any suitable material with a short T1 such as Gd-DTPA or oil can be used as a coordinate indicator. With these modifications the frame can be used for MR imaging in a manner similar to that of CT-guided stereotactic biopsy. Such a system has advantages in regions (such as the brainstem) where detail may be unsatisfactory with CT, as well as in patients with tumors that display only a mass effect on CT but more specific features with MR imaging.

With MR imaging, many lesions display the relatively nonspecific features of an increased T1 and an increased T2; stereotactic biopsy may permit a specific diagnosis in such cases. Stereotactic biopsy may help also to explain the changes seen on MR scans and to assess the accuracy of MR imaging in distinguishing tumor from edema with different pulse sequences. No technique has heretofore been available as a "gold standard" for assessing the accuracy of the various MR imaging approaches to this problem, including the use of intravenous Gd-DTPA as a paramagnetic contrast agent [13].

The current frame is being adapted to allow stereotactic biopsy in the coronal and sagittal planes, which should represent a further useful development. Stereotactic biopsy represents an extension of the scope of MR imaging and promises to have valuable clinical and research applications.

ACKNOWLEDGMENT

We thank Trent Wells for his advice and for supplying the MR localizer.

REFERENCES

1. Munding F, Birg W, Klar M. Computer-assisted stereotactic brain operations by means including computerised axial tomography. *Appl Neurophysiol* 1978;41:169-182
2. Perry JH, Rosenbaum AE, Lunsford LD, Swink CA, Zorub DS. Computed tomography guided stereotactic surgery: conception and development of a new stereotactic methodology. *Neurosurgery* 1980;7:376-381
3. Leksell L, Jernberg B. Stereotaxis and tomography. A technical note. *Acta Neurochir (Wien)* 1980;52:1-7
4. Thomas DGT, Anderson RE, du Boulay GH. CT-directed ster-

Fig. 3.—Case 1. Contrast-enhanced CT scan (A) and IR 1500/500/44 (B) scans. Biopsies were obtained in relation to ring within lesions (B, arrow).





Fig. 4.—Case 2. Contrast-enhanced CT (A) and SE 1500/80 (B) scans. Abnormal area in B (arrow) was biopsied.

- eotactic surgery with the Brown-Roberts-Wells (BRW) system. *J Neurol Neurosurg Psychiatry* **1983**;46:369–370
5. Bydder GM, Steiner RE, Young IR, et al. Clinical NMR imaging of the brain: 140 cases. *AJNR* **1982**;3:459–480, *AJR* **1982**;139:215–236
 6. Brant-Zawadzki M, Davis PL, Crooks L, et al. NMR demonstration of cerebral abnormalities: comparison with CT. *AJNR* **1983**;4:117–124, *AJR* **1983**;140:847–856
 7. Leksell L, Leksell D, Schwebel J. Stereotaxis and nuclear magnetic resonance. *J Neurol Neurosurg Psychiatry* **1985**;48:14–18
 8. Leksell L, Herner T, Leksell D, Persson B, Lindquist C. Visualisation of stereotactic radiolesions by nuclear magnetic resonance. *J Neurol Neurosurg Psychiatry* **1985**;48:19–20
 9. Roberts TS, Brown R. Technical and clinical aspects of CT-directed stereotaxis. *Appl Neurophysiol* **1980**;43:170–171
 10. Brown RA, Roberts TS, Osborn AG. Stereotaxic frame and computer software for CT-directed neurosurgical localization. *Invest Radiol* **1980**;15:308–312
 11. Brown RA, Roberts T, Osborn AG. Simplified CT-guided stereotaxic biopsy. *AJNR* **1981**;2:181–184
 12. Young IR, Burl M, Clarke GJ, et al. Magnetic resonance properties of hydrogen: imaging the posterior fossa. *AJNR* **1981**;2:487–489, *AJR* **1981**;137:895–901
 13. Carr DH, Brown J, Bydder GM, et al. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. *AJR* **1984**;143:215–224